1. Angiopoietin-like growth factor-derived peptides as biological activators of adipose-derived mesenchymal stromal cells.
- Author
-
Schumacher A, Mucha P, Puchalska I, Deptuła M, Wardowska A, Tymińska A, Filipowicz N, Mieczkowska A, Sachadyn P, Piotrowski A, Pikuła M, and Cichorek M
- Subjects
- Humans, Cell Survival drug effects, Cells, Cultured, Peptides pharmacology, Cell Movement drug effects, Apoptosis drug effects, Cytokines metabolism, Mesenchymal Stem Cells drug effects, Mesenchymal Stem Cells metabolism, Adipose Tissue cytology, Adipose Tissue metabolism, Cell Differentiation drug effects, Angiopoietin-like Proteins metabolism, Chondrogenesis drug effects
- Abstract
Adipose-derived mesenchymal stromal cells (AD-MSCs) are an essential issue in modern medicine. Extensive preclinical and clinical studies have shown that mesenchymal stromal/stem cells, including AD-MSCs, have specific properties (ability to differentiate into other cells, recruitment to the site of injury) of particular importance in the regenerative process. Ongoing research aims to elucidate factors supporting AD-MSC culture and differentiation in vitro. Angiopoietin-like proteins (ANGPTLs), known for their pleiotropic effects in lipid and glucose metabolism, may play a significant role in this context. Regeneration is a complex and dynamic process controlled by many factors. ANGPTL6 (Angiopoietin-related growth factor, AGF), among many activities modulated the biological activity of stem cells. This study examined the influence of synthesized AGF-derived peptides, designated as AGF9 and AGF27, on AD-MSCs. AGF9 and AGF27 enhanced the viability and migration of AD-MSCs and acted as a chemotactic factor for these cells. AGF9 stimulated chondrogenesis and lipid synthesis during AD-MSCs differentiation, influenced AD-MSCs cytokine secretion and modulated transcriptome for such basic cell activities as migration, transport of molecules, and apoptosis. The ability of AGF9 to modulate the biological activity of AD-MSCs warrants the consideration of this peptide a noteworthy therapeutic agent that deserves further investigation for applications in regenerative medicine., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: M. Pikula, P. Sachadyn, A. Piotrowski reports financial support was provided by National Centre for Research and Development. P. Mucha, I. Puchalska, M. Pikula, A. Schumacher, M. Cichorek, A. Wardowska, M. Deptula, A. Piotrowski, N. Filipowicz, P. Sachadyn has patent #Patent number: PL236332 B1, 28 Dec 2020 issued to assignee. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF